Tracer Development

We help nuclear medicine and radiopharmaceutical companies amplify your insights

Deeper understanding leads to consistency. AIQ Solutions is a vital partner within the radiopharmaceuticals space.

Every Disease is Different.
Every Person is Different. Every Lesion is Different.

AIQ HAS IMAGING ANALYSIS SOLUTIONS

With the AIQ Collaborative Workflow, the steps are customizable to meet the specific requirements for clinical studies.


Upload Images
Identification
Quantification
Matching
Classification

Consistent and Comprehensive Assessment

AI-driven algorithms allow for reproducible and repeatable imaging analysis, eliminating inter- and intra-physician variability.

Weisman et al., AJ, World Molecular Imaging Congress (WMIC) 2021.  Click to View Full Poster

Quantification of Longitudinal Tracer Changes

TRAQinform TR technology matches every lesion or organ across scans and quantifies changes in tracer uptake with high sensitivity and specificity.

Determination of Tracer Concordance

Enhanced capabilities allow for custom models to compare tracer uptake between multiple radiotracers for each organ and lesion. AIQ Solutions quantifies and characterizes tracer uptake for each individual lesion as well as individual organ and determines correlation with clinical outcomes.

Analysis of Tracer Bio Distribution Patterns

Spatiotemporal analysis reveals heterogeneity in the signal range between different patients and between different regions of interest within the same patient.

Bio distribution of AT-01 in a representative healthy subject (A) and patient with systemic AL amyloidosis (B). Maximum intensity projection and coronal views in (A) show physiologic uptake was observed in the parotid, salivary and thyroid glands, as well as saliva, stomach lumen, urine in ureters, and bladder. No myocardial uptake was observed: Click to View Full Poster

A VALUED PARTNER FOR YOUR STUDIES

AIQ COLLABORATION

AIQ’s collaboration consists of a workflow that is simple and easy to implement without interruption for single and multi-site studies. We pride ourselves on building a partnership that upholds our company’s values and value proposition. We also partner with CROs to acquire imaging data.

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

This will close in 40 seconds

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.

This will close in 40 seconds

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September 2018. He has led AIQ through two rounds of equity financing, team construction, product commercialization, and international expansion. Before joining the AIQ team, Eric was President and CEO of Swallow Solutions LLC, a medical device start-up with both therapeutic devices and functional beverages for dysphagia patients. Before that, Eric was General Manager, Premium Anesthesia and Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a $220 million global business and a large team spread over three continents. He has also held a series of marketing and business development roles at Baxter Healthcare, including Director of Renal Products and Services for the Latin America region. Eric has a B.S. in Chemical Engineering from Rice University and both an MBA and Master of Engineering Management degrees from the Kellogg School of Business. He lives in Madison with his wife and two children.

This will close in 40 seconds

Information on this page is intended for research use only. Applications and/or claims listed are not currently cleared for use in treatment of patients.